
    
      We administered three cycles FOLFOX4 plus on TAC (oxaliplatin, FUDR and MMC) or FOLFOX4 only
      to primary colorectal tumor resected patients with unresected liver metastasis. The study
      endpoints were resection rate of liver metastasis, progression-free survival, overall
      survival as evaluated by intent-to-treat analysis.
    
  